Press Release

Avidity – $16 Million Series B

January 12, 2017

Palo Alto – January 12, 2017 – Cooley advised Avidity Biosciences on its $16 million Series B financing. The round comprises $10 million in new capital and $6 million in convertible debt.

Takeda Pharmaceuticals, through its ventures group, led the round, with new and existing investor participation from Alethea Capital, Alexandria Real Estate Equities, Brace Pharma, EcoR1 Capital, F-Prime Capital Partners, Moore Venture Partners and Tavistock Life Sciences.

Avidity is a privately held biotech company pioneering a new class of precision medicines – Antibody-siRNA Conjugates (ASC) – which combine the strengths of monoclonal antibodies and siRNA-based therapeutics. Avidity is working with partners to discover best-in-class drug candidates against important undrugged therapeutic targets.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 900 lawyers across 12 offices in the United States, China and Europe.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may have been generated with the assistance of artificial intelligence (AI) in accordance with our AI Principles, may be considered Attorney Advertising and is subject to our legal notices.